Dental Care Clinics in Marlboro, MA Accepting Medicare
2 Dental Care Clinics found. Showing 1 - 2
 Carvalho And Roth Orthodontics, Llp Dentist - Orthodontics and Dentofacial Orthopedics Medicare: Not Enrolled in Medicare Practice Location: 126 Union Street, Marlboro, MA 01752 Phone: 508-485-8788 Fax: 508-485-5669 |
Unique Dental Care Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 11 Court Street, Marlboro, MA 01752 Phone: 508-485-0008 Fax: 508-485-3919 |
News Archive
Gleevec shows great promise in preventing cancer recurrence
Gleevec, a pill developed in conjunction with the Oregon Health & Science University Cancer Institute is again showing excellent results in preventing a cancer recurrence.
FDA approves Teligent's sNDA for CEFOTAN (cefotetan) for Injection
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's supplemental new drug application (sNDA) from the U.S. Food and Drug Administration (FDA) for CEFOTAN (cefotetan) for Injection.
AS03 and MF59 adjuvants increase immune responses to two doses of H7N9 influenza vaccine
In a phase 2 trial that included nearly 1,000 adults, the AS03 and MF59 adjuvants (a component that improves immune response of inactivated influenza vaccines) increased the immune responses to two doses of an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest amount of antibody response, according to a study in the July 21 issue of JAMA.
Researchers develop new method to predict people's biological age
New research has shed light on the molecular changes that occur in our bodies as we age. In the largest study of its kind, an international group of researchers, including experts from the University of Exeter's Medical School, examined expression of genes in blood samples from 15,000 people across the world.
Study finds no added benefit from sipuleucel-T in men with metastatic prostate cancer
Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T.
› Verified 9 days ago